Retinal Disorders Treatment Market

Retinal Disorders Treatment Market (Indication: Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, and Others; Therapeutic Class: Anti-VEGF Agents and Others; Dosage Form: Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Sales) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Advancements in Gene-therapy and Stem-cell Therapy to Bolster Market Growth

Retinal disorders have received considerable attention from researchers and other experts over the course of the past couple of decades. However, prior to that timeframe, retinal disorders were largely sidelined as the primary cause of blindness in the blindness programs in most of developing regions. A number of factors, including high costs involved in the treatment of retinal disorders, steep costs, and unreliability of the equipment utilized were some of the common factors that led to a sluggish growth of the retinal disorders treatment market in several developing regions. Over the past few years, advancements in technology coupled with promising findings from research and development activities have contributed to the overall development of the global retinal disorders treatment market– a trend that is projected to continue over the duration of the forecast period.

Increasing prevalence of retinal disorders in both, developing as well as developed regions of the world is expected to drive innovations, accelerate new treatments, and play an important role in increasing investments toward the overall development of the retinal disorders treatment market. Furthermore, the growing prevalence of diabetes around the world is another factor that is expected to augment the number of patients suffering from retinal disorders– a factor that is projected to boost the growth of the global retinal disorders treatment market during the assessment period. The increasing support offered by governments, particularly in developing regions has led to a considerable growth of the overall awareness pertaining to various retinal disorders due to which, the demand for retinal disorders treatment has witnessed a notable spike. This factor is anticipated to boost the prospects of the global retinal disorders treatment market during the stipulated timeframe of the study.

At the back of these factors, the global retinal disorders treatment market is on the course to surpass the US$ 19 Bn mark by the end of 2030.

New Technologies Set to Transform Future of Retinal Disorders Treatment

Technological advancements are set to play a key role in the overall growth of the global retinal disorders treatment market in the upcoming years. Groundbreaking breakthroughs and advancements in bionics, genetics, and stem-cell therapy are expected to transform the future of retinal disorders treatment in the upcoming decade. In developed regions wherein the preventable causes of blindness are detected early, owing to routine checkups and robust healthcare ecosystem, retinal degeneration has emerged as one of the top causes of blindness or visual impairment. Advancements across several new frontiers are expected to pave the way for new retinal disorders treatments for all the major forms of retinal disorders. Advancements in gene therapy, functional prostheses, and growing interest in bionic eyes are projected to play a vital role in boosting the growth of the global retinal disorders treatment market during the forecast period. While gene therapy is likely to emerge as a promising retinal disorder treatment, cell regeneration or stem-cell therapy has offered considerable promise in the treatment of blindness, especially in the later stages of the disease. Advancements in technology coupled with research and development activities are expected to play a key role in boosting the growth of the global retinal disorders treatment market during the assessment period.

Links Between COVID-19 and Microvascular Alterations to Increase Demand

The onset of the COVID-19 pandemic is expected to have a moderate impact on the overall growth of the global retinal disorders treatment market in 2020. While the major focus is projected to remain toward the discovery of new vaccine, research and development activities in other branches of the medical sectors are likely to continue as per the initial timeline. Research activities are also anticipated to evaluate the presence of retinal alterations among patients suffering from the novel COVID-19 infection. Due to the constant fear of contracting the virus, doctors and specialists are expected to rely on telehealth services. Although the trends suggest that patients are willing to delay retinal disorders treatment due to the ongoing pandemic, the market is likely to show signs of recovery toward the last quarter of 2020.

Analysts’ Viewpoint

The global retinal disorders treatment market is anticipated to expand at a healthy CAGR of ~7% during the forecast period. The market growth is primarily driven by increasing prevalence of retinal disorders worldwide, advancements in technology, including gene therapy and stem-cell therapy, research and development activities, and rising awareness regarding recent research findings and progress made in the retinal disorders treatment market. Market players should focus on research and development activities and continue to explore the potential of different technologies that could be utilized for retinal disorders treatment.

Retinal Disorders Treatment Market: Overview

  • Macular degeneration is of two types: wet age-related macular degeneration and dry age-related macular degeneration. Diabetic retinopathy is one of the common diabetic eye disorders characterized by damaged blood vessels in the retina. The damaged blood vessels and nerves lead to vision impairment, blurring of vision, and eye hemorrhage. If left untreated, it could lead to retinal detachment and blindness.
  • The global retinal disorders treatment market is projected to expand at a moderate pace due to rise in prevalence of retinal disorders, owing to increase in geriatric patient population, new product launches, high annual cost of therapy (ACOT), and surge in number of eye care centers leading to increased product utilization

Retinal Disorders Treatment Market: Drivers

  • Rise in prevalence of retinal disorders due to increase in geriatric patient population boosts the growth of the global retinal disorders treatment market. Age-related macular degeneration (AMD) is the leading cause of irreversible blindness across the globe, affecting around 196 million in 2019 and anticipated to increase to 288 million by 2040. Prevalence estimates are on late AMD, involving neovascular AMD, and geographic atrophy. In the U.S., the number of patients suffering from AMD is 11 million. This number is expected to double to nearly 22 million by 2050.
  • Prevalence of other retinal disorders was 93 million people with diabetic retinopathy, 21 million people with diabetic macular edema, and 28 million people with vision-threatening diabetic retinopathy
  • New product launches and high annual cost of therapy (ACOT) also fuel the growth of the retinal disorders treatment market in terms of revenue. New anti-vascular endothelial growth factor (anti-VEGF) drugs have been launched to treat the neovascular (wet) form of AMD, along with numerous other retinal conditions. Anti-VEGFs have improved therapy outcomes for these conditions; however, these incur high cost.
  • In 2007, Lucentis became the first anti-VEGF launched in Canada and approved for wet AMD as well as other major retinal diseases. It was quickly recognized as the new gold standard for treatment. In 2013, Eylea was also approved for AMD and launched at a marginally lower price; other indications were added later.

Increase in Healthcare Spending and Improvement in Healthcare Infrastructure

  • Increase in R&D activities, rise in number of patients suffering from diseases, and rapid expansion of healthcare and biopharmaceutical industries in developed and developing countries are likely to boost advancements in therapies in the retinal disorders treatment market during the forecast period
  • For instance, Lucentis and Eylea accounted for 2.8% of total pharmaceutical sales in Canada in 2017

Market Segmentation: Retinal Disorders Treatment Market

  • In terms of indication, the global retinal disorders treatment market has been divided into macular degeneration, diabetic retinopathy, diabetic macular edema, and others. Macular degeneration has been split into dry macular degeneration and wet macular degeneration.
  • Based on therapeutic class, the global retinal disorders treatment market has been categorized into anti-VEGF agents and others
  • In terms of dosage form, the global retinal disorders treatment market has been segregated into gels, eye solutions, capsules & tablets, eye drops, and ointments
  • Based on distribution channel, the global retinal disorders treatment market has been classified into hospital pharmacies, retail pharmacies, and online sales
  • Each of the segments has been analyzed in detail for retinal disorders treatment trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The retinal disorders treatment market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2030, along with market size estimations.

Regional Overview: Retinal Disorders Treatment Market

  • In terms of region, the global retinal disorders treatment market has been segmented into the U.S., Europe, China, Russia, and Rest of the world
  • The U.S. dominated the global retinal disorder treatment market in 2019 due to highly structured healthcare industry, early adoption of new products, and presence of major players. The retinal disorders treatment market in China is projected to expand at the highest CAGR during the forecast period, owing to a large untapped population and rise in the adoption of treatment. Diagnosis and treatment rates have increased due to rise in disposable income and health awareness. This has led to an increase in the adoption of macular degeneration drugs.
  • Current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the report for the period from 2018 to 2030, along with their CAGRs for the period from 2020 to 2030
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which are estimated to help new companies willing to enter the retinal disorders treatment market and existing companies to increase market share, and in the decision-making process

Major Players

  • The report concludes with the company profiles section that includes key information about the major players in the global retinal disorders treatment market
  • Leading players analyzed in the report are
    • Allergan plc
    • Bayer AG, F.
    • Hoffmann-La Roche Ltd.
    • Graybug Vision, Inc.
    • Kubota Pharmaceutical Holdings Co., Ltd.
    • Novartis AG, Pfizer, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Santen Pharmaceutical Co., Ltd.
    • Takeda Pharmaceutical Company Limited
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Frequently Asked Questions

What is the total market worth of retinal disorders treatment market?

The global retinal disorders treatment market was worth US$ 9.18 Bn and is projected to reach a value of US$ 19 Bn by the end of 2030

What is the anticipated CAGR of retinal disorders treatment market in forecast period?

Retinal disorders treatment market is anticipated to grow at a CAGR of 7% during the forecast period

Which region is expected to project highest market share in retinal disorders treatment market?

North America accounted for a major share of the global retinal disorders treatment market

What are the key driving factors for growth of retinal disorders treatment market?

Retinal disorders treatment market is driven by increasing prevalence of retinal disorders worldwide, advancements in technology, including gene therapy and stem-cell therapy, research and development activities, and rising awareness regarding recent research findings

Who are the key players in the global retinal disorders treatment market?

Key players in the global retinal disorders treatment market include Allergan plc, Bayer AG, F. Hoffmann-La Roche Ltd., Graybug Vision, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Retinal Disorders Treatment Market

4. Market Overview

    4.1.  Introduction & Overview

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunities

    4.3. Global Retinal Disorders Treatment Market Analysis and Forecast, 2018–2030

5. Market Outlook

    5.1. COVID-19 Pandemics Impact on Industry

    5.2. Clinical Trial Analysis

    5.3. Regulatory Scenario

    5.4. Pipeline Analysis

    5.5. Key Potential Customers

    5.6. Key Vendor and Distributor Analysis

    5.7. Key Industry Events

    5.8. Reimbursement Scenario

    5.9. Retinal Disorders: Epidemiology Forecast

6. Global Retinal Disorders Treatment Market Analysis and Forecast, by Indication

    6.1. Introduction & Definition    

    6.2. Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

        6.2.1. Macular Degeneration

            6.2.1.1. Dry Macular Degeneration

            6.2.1.2. Wet Macular Degeneration

        6.2.2. Diabetic Retinopathy

        6.2.3. Diabetic Macular Edema

        6.2.4. Others

    6.3. Global Retinal Disorders Treatment Market Attractiveness Analysis, by Indication

7. Global Retinal Disorders Treatment Market Analysis and Forecast, by Therapeutic Class

    7.1. Introduction & Definition    

    7.2. Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

        7.2.1. Anti-VEGF Agents

        7.2.2. Others

    7.3. Global Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class

8. Global Retinal Disorders Treatment Market Analysis and Forecast, by Dosage Form

    8.1. Introduction & Definition    

    8.2. Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

        8.2.1. Gels

        8.2.2. Eye Solutions

        8.2.3. Capsules & Tablets

        8.2.4. Eye Drops

        8.2.5. Ointments

    8.3. Global Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form

9. Global Retinal Disorders Treatment Market Analysis and Forecast, by Distribution Channel

    9.1. Introduction & Definition    

    9.2. Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        9.2.1. Hospital Pharmacies

        9.2.2. Retail Pharmacies

        9.2.3. Online Sales

    9.3. Global Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel

10. Global Retinal Disorders Treatment Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Region

        10.2.1. U.S.

        10.2.2. Europe

        10.2.3. China

        10.2.4. Russia

        10.2.5. Rest of the World (RoW)

    10.3. Global Retinal Disorders Treatment Market Attractiveness Analysis, by Region

11. U.S. Retinal Disorders Treatment Market Analysis and Forecast

    11.1. Introduction

    11.2. U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

        11.2.1. Macular Degeneration

            11.2.1.1. Dry Macular Degeneration

            11.2.1.2. Wet Macular Degeneration

        11.2.2. Diabetic Retinopathy

        11.2.3. Diabetic Macular Edema

        11.2.4. Others

    11.3. U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

        11.3.1. Anti-VEGF Agents

        11.3.2. Others

    11.4. U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

        11.4.1. Gels

        11.4.2. Eye Solutions

        11.4.3. Capsules & Tablets

        11.4.4. Eye Drops

        11.4.5. Ointments

    11.5. U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Sales

    11.6. U.S. Retinal Disorders Treatment Market Attractiveness Analysis

        11.6.1. By Indication

        11.6.2. By Therapeutic Class

        11.6.3. By Dosage Form

        11.6.4. By Distribution Channel

12. Europe Retinal Disorders Treatment Market Analysis and Forecast

    12.1. Introduction

    12.2. Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

        12.2.1. Macular Degeneration

            12.2.1.1. Dry Macular Degeneration

            12.2.1.2. Wet Macular Degeneration

        12.2.2. Diabetic Retinopathy

        12.2.3. Diabetic Macular Edema

        12.2.4. Others

    12.3. Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

        12.3.1. Anti-VEGF Agents

        12.3.2. Others

    12.4. Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

        12.4.1. Gels

        12.4.2. Eye Solutions

        12.4.3. Capsules & Tablets

        12.4.4. Eye Drops

        12.4.5. Ointments

    12.5. Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        12.5.1. Hospital Pharmacies

        12.5.2. Retail Pharmacies

        12.5.3. Online Sales

    12.6. Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Europe Retinal Disorders Treatment Market Attractiveness Analysis

        12.7.1. By Indication

        12.7.2. By Therapeutic Class

        12.7.3. By Dosage Form

        12.7.4. By Distribution Channel

        12.7.5. By Country/Sub-region

13. China Retinal Disorders Treatment Market Analysis and Forecast

    13.1. Introduction

    13.2. China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

        13.2.1. Macular Degeneration

            13.2.1.1. Dry Macular Degeneration

            13.2.1.2. Wet Macular Degeneration

        13.2.2. Diabetic Retinopathy

        13.2.3. Diabetic Macular Edema

        13.2.4. Others

    13.3. China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

        13.3.1. Anti-VEGF Agents

        13.3.2. Others

    13.4. China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

        13.4.1. Gels

        13.4.2. Eye Solutions

        13.4.3. Capsules & Tablets

        13.4.4. Eye Drops

        13.4.5. Ointments

    13.5. China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        13.5.1. Hospital Pharmacies

        13.5.2. Retail Pharmacies

        13.5.3. Online Sales

    13.6. China Retinal Disorders Treatment Market Attractiveness Analysis

        13.6.1. By Indication

        13.6.2. By Therapeutic Class

        13.6.3. By Dosage Form

        13.6.4. By Distribution Channel

14. Russia Retinal Disorders Treatment Market Analysis and Forecast

    14.1. Introduction

    14.2. Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

        14.2.1. Macular Degeneration

            14.2.1.1. Dry Macular Degeneration

            14.2.1.2. Wet Macular Degeneration

        14.2.2. Diabetic Retinopathy

        14.2.3. Diabetic Macular Edema

        14.2.4. Others

    14.3. Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

        14.3.1. Anti-VEGF Agents

        14.3.2. Others

    14.4. Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

        14.4.1. Gels

        14.4.2. Eye Solutions

        14.4.3. Capsules & Tablets

        14.4.4. Eye Drops

        14.4.5. Ointments

    14.5. Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        14.5.1. Hospital Pharmacies

        14.5.2. Retail Pharmacies

        14.5.3. Online Sales

    14.6. Russia Retinal Disorders Treatment Market Attractiveness Analysis

        14.6.1. By Indication

        14.6.2. By Therapeutic Class

        14.6.3. By Dosage Form

        14.6.4. By Distribution Channel

15. Rest of the World Retinal Disorders Treatment Market Analysis and Forecast

    15.1. Introduction

    15.2. Rest of the World Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

        15.2.1. Macular Degeneration

            15.2.1.1. Dry Macular Degeneration

            15.2.1.2. Wet Macular Degeneration

        15.2.2. Diabetic Retinopathy

        15.2.3. Diabetic Macular Edema

        15.2.4. Others

    15.3. Rest of the World Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

        15.3.1. Anti-VEGF Agents

        15.3.2. Others

    15.4. Rest of the World Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

        15.4.1. Gels

        15.4.2. Eye Solutions

        15.4.3. Capsules & Tablets

        15.4.4. Eye Drops

        15.4.5. Ointments

    15.5. Rest of the World Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        15.5.1. Hospital Pharmacies

        15.5.2. Retail Pharmacies

        15.5.3. Online Sales

    15.6. Rest of the World Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        15.6.1. Canada

        15.6.2. India

        15.6.3. Japan

        15.6.4. Australia

        15.6.5. Brazil

        15.6.6. Rest of Rest of the World

    15.7. Rest of the World Retinal Disorders Treatment Market Attractiveness Analysis

        15.7.1. By Indication

        15.7.2. By Therapeutic Class

        15.7.3. By Dosage Form

        15.7.4. By Distribution Channel

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Position Analysis, by Company, 2019

    16.2. Company Profiles

        16.2.1. Allergan plc

            16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.1.2. Growth Strategies

            16.2.1.3. SWOT Analysis

        16.2.2. Bayer AG

            16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2.2. Growth Strategies

            16.2.2.3. SWOT Analysis

        16.2.3. F. Hoffmann-La Roche Ltd.

            16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.3.2. Growth Strategies

            16.2.3.3. SWOT Analysis

        16.2.4. Graybug Vision, Inc.

            16.2.4.1. Company Overview (HQ, Business Segments)

            16.2.4.2. Growth Strategies

            16.2.4.3. SWOT Analysis

        16.2.5. Kubota Pharmaceutical Holdings Co., Ltd.

            16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.5.2. Growth Strategies

            16.2.5.3. SWOT Analysis

        16.2.6. Novartis AG

            16.2.6.1. Company Overview (HQ, Business Segments)

            16.2.6.2. Growth Strategies

            16.2.6.3. SWOT Analysis

        16.2.7. Pfizer, Inc.

            16.2.7.1. Company Overview (HQ, Business Segments)

            16.2.7.2. Growth Strategies

            16.2.7.3. SWOT Analysis

        16.2.8. Regeneron Pharmaceuticals, Inc.

            16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.8.2. Growth Strategies

            16.2.8.3. SWOT Analysis

        16.2.9. Santen Pharmaceutical Co., Ltd.

            16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.9.2. Growth Strategies

            16.2.9.3. SWOT Analysis

        16.2.10. Takeda Pharmaceutical Company Limited

            16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.10.2. Growth Strategies

            16.2.10.3. SWOT Analysis

List of Tables

Table 01: Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 02: Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

Table 03: Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

Table 04: Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 05: Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 06: U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 07: U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

Table 08: U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

Table 09: U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 10: Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 11: Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

Table 12: Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

Table 13: Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 14: Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 15: China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 16: China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

Table 17: China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

Table 18: China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 19: Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 20: Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

Table 21: Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

Table 22: Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 23: Rest of the World (ROW) Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 24: Rest of the World (ROW) Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

Table 25: Rest of the World (ROW) Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

Table 26: Rest of the World (ROW) Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 27: Rest of the World (ROW) Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

List of Figures

Figure 01: Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Retinal Disorders Treatment Market Value Share, by Indication, 2019

Figure 03: Global Retinal Disorders Treatment Market Value Share, by Dosage Form, 2019

Figure 04: Global Retinal Disorders Treatment Market Value Share, by Therapeutic Class, 2019

Figure 05: Global Retinal Disorders Treatment Market Value Share, by Distribution Channel, 2019

Figure 06: Global Retinal Disorders Treatment Market Value Share, by Region, 2019

Figure 07: Clinical Trial Analysis, by Phase

Figure 08: Clinical Trial Analysis, by Status

Figure 09: Clinical Trial Analysis, by Completion and Termination Rate

Figure 10: Clinical Trial Analysis, by Region

Figure 11: Global Retinal Disorders Treatment Market Value Share Analysis, by Indication, 2019 and 2030

Figure 12: Global Retinal Disorders Treatment Market Attractiveness Analysis, by Indication, 2020–2030

Figure 13: Global Retinal Disorders Treatment Market Value (US$ Mn), by Macular Degeneration, 2018–2030

Figure 14: Global Retinal Disorders Treatment Market Value (US$ Mn), by Diabetic Retinopathy, 2018–2030

Figure 15: Global Retinal Disorders Treatment Market Value (US$ Mn), by Diabetic Macular Edema, 2018–2030

Figure 16: Global Retinal Disorders Treatment Market Value (US$ Mn), by Others (retinal vein occlusion, etc.), 2018–2030

Figure 17: Global Retinal Disorders Treatment Market Value Share Analysis, by Therapeutic Class, 2019 and 2030

Figure 18: Global Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class, 2020–2030

Figure 19: Global Retinal Disorders Treatment Market Value (US$ Mn), by Anti-VEGF Agents, 2018–2030

Figure 20: Global Retinal Disorders Treatment Market Value (US$ Mn), by Others (anti-inflammatory drugs, etc.), 2018–2030

Figure 21: Global Retinal Disorders Treatment Market Value Share Analysis, by Dosage Form, 2019 and 2030

Figure 22: Global Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form, 2020–2030

Figure 23: Global Retinal Disorders Treatment Market Value (US$ Mn), by Gels, 2018–2030

Figure 24: Global Retinal Disorders Treatment Market Value (US$ Mn), by Eye Solutions, 2018–2030

Figure 25: Global Retinal Disorders Treatment Market Value (US$ Mn), by Capsules & Tablets, 2018–2030

Figure 26: Global Retinal Disorders Treatment Market Value (US$ Mn), by Eye Drops, 2018–2030

Figure 27: Global Retinal Disorders Treatment Market Value (US$ Mn), by Ointments, 2018–2030

Figure 28: Global Retinal Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 29: Global Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 30: Global Retinal Disorders Treatment Market Value (US$ Mn), by Hospital Pharmacies, 2018–2030

Figure 31: Global Retinal Disorders Treatment Market Value (US$ Mn), by Retail Pharmacies, 2018–2030

Figure 32: Global Retinal Disorders Treatment Market Value (US$ Mn), by Online Sales, 2018–2030

Figure 33: Global Retinal Disorders Treatment Market Value Share Analysis, by Region, 2019 and 2030

Figure 34: Global Retinal Disorders Treatment Market Analysis, by Region

Figure 35: U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 36: U.S. Retinal Disorders Treatment Market Value Share Analysis, by Indication, 2019 and 2030

Figure 37: U.S. Retinal Disorders Treatment Market Attractiveness Analysis, by Indication, 2020–2030

Figure 38: U.S. Retinal Disorders Treatment Market Value Share Analysis, by Therapeutic Class, 2019 and 2030

Figure 39: U.S. Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class, 2020–2030

Figure 40: U.S. Retinal Disorders Treatment Market Value Share Analysis, by Dosage Form, 2019 and 2030

Figure 41: U.S. Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form, 2020–2030

Figure 42: U.S. Retinal Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 43: U.S. Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 44: Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 45: Europe Retinal Disorders Treatment Market Value Share Analysis, by Indication, 2019 and 2030

Figure 46: Europe Retinal Disorders Treatment Market Attractiveness Analysis, by Indication, 2020–2030

Figure 47: Europe Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class, 2020–2030

Figure 48: Europe Retinal Disorders Treatment Market Value Share Analysis, by Dosage Form, 2019 and 2030

Figure 49: Europe Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form, 2020–2030

Figure 50: Europe Retinal Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 51: Europe Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 52: Europe Retinal Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 53: Europe Retinal Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 54: China Retinal Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 55: China Retinal Disorders Treatment Market Value Share Analysis, by Indication, 2019 and 2030

Figure 56: China Retinal Disorders Treatment Market Attractiveness Analysis, by Indication, 2020–2030

Figure 57: China Retinal Disorders Treatment Market Value Share Analysis, by Therapeutic Class, 2019 and 2030

Figure 58: China Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class, 2020–2030

Figure 59: China Retinal Disorders Treatment Market Value Share Analysis, by Dosage Form, 2019 and 2030

Figure 60: China Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form, 2020–2030

Figure 61: China Retinal Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 62: China Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 63: Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 64: Russia Retinal Disorders Treatment Market Value Share Analysis, by Indication, 2019 and 2030

Figure 65: Russia Retinal Disorders Treatment Market Attractiveness Analysis, by Indication, 2020–2030

Figure 66: Russia Retinal Disorders Treatment Market Value Share Analysis, by Therapeutic Class, 2019 and 2030

Figure 67: Russia Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class, 2020–2030

Figure 68: Russia Retinal Disorders Treatment Market Value Share Analysis, by Dosage Form, 2019 and 2030

Figure 69: Russia Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form, 2020–2030

Figure 70: Russia Retinal Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 71: Russia Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 72: Rest of the World (ROW) Retinal Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 73: Rest of the World (ROW) Retinal Disorders Treatment Market Value Share Analysis, by Indication, 2019 and 2030

Figure 74: Rest of the World (ROW) Retinal Disorders Treatment Market Attractiveness Analysis, by Indication, 2020–2030

Figure 75: Rest of the World (ROW) Retinal Disorders Treatment Market Value Share Analysis, by Therapeutic Class, 2019 and 2030

Figure 76: Rest of the World (ROW) Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class, 2020–2030

Figure 77: Rest of the World (ROW) Retinal Disorders Treatment Market Value Share Analysis, by Dosage Form, 2019 and 2030

Figure 78: Rest of the World (ROW) Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form, 2020–2030

Figure 79: Rest of the World (ROW) Retinal Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 80: Rest of the World (ROW) Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 81: Rest of the World (ROW) Retinal Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 82: Rest of the World (ROW) Retinal Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Copyright © Transparency Market Research, Inc. All Rights reserved